Anti-CDK16 TripleA Polyclonal antibody in breast cancer research

Breast cancer is the most common malignancy and the leading cause of cancer-associated death in women.

This study (Li, X. et al., 2022) reports new evidence showing that cyclin-dependent kinase 16 (CDK16) plays a critical role in triple-negative breast cancer and its potential role as a therapeutic target for breast cancer.

Here are the significant findings of the study:

👉 CDK16 is highly expressed in breast cancer, particularly in triple-negative breast cancer.
👉 The elevated CDK16 expression is correlated with poor outcomes in breast cancer patients.
👉 CDK16 can improve cancer cells' proliferation and migration ability in vitro and promote tumor growth and metastasis in vivo.
👉 Both genetic knockdown and pharmacological inhibition of CDK16 significantly suppress the tumor progression.

The image shows the immunochemical staining of breast cancer tissue from a female, age 50 (source: the Human Protein Atlas).

The immunohistochemistry on breast cancer tissue was performed using our Anti-CDK16 TripleA Polyclonal antibody (HPA001366).

Whole artical read here: https://lnkd.in/dKw6rCwy.